Business
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
Key highlights from the first quarter of operations under the expanded management team include the following: Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable preliminary determinations already received from the FDA Office of Generic Drugs on bioequivalence, labeling, drug product, drug substance, and safety.Initiation of commercial manufacturing of Ketamine at the 1 million dose per month level with recent FDA inspection of the manufacturi
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"image","alt":"NRx Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"NRx Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oQlnKXAw77IR4.RQxkfHUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/4ef53875d129fcc14f2614dd5795d5a9","width":300,"height":300}},"lazy":false},{"type":"text","content":"Key highlights from the first quarter of operations under the expanded management team include the following:","length":109,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Anticipated FDA decision on the Company's ANDA for Preservative-Free Ketamine in Q3 2026, with favorable preliminary determinations already received from the FDA Office of Generic Drugs on bioequivalence, labeling, drug product, drug substance, and safety.","length":260,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiation of commercial manufacturing of Ketamine at the 1 million dose per month level with recent FDA inspection of the manufacturing facility and granting of inspection status consistent with launch of an ANDA drug.","length":219,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed a Type C meeting with the FDA Division of Psychiatry Products and CDER leadership, in which the Agency expressed openness to existing clinical trial data and Real World Evidence supporting approval without additional trials.","length":234,"tagName":"p"}]},{"val":[{"type":"text","content":"Presidential Executive Order signed and Congressional Appropriations Language filed encouraging the use of Real World Evidence in the approval of drugs for suicidal depression and PTSD.","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointment of Prof. Joshua Brown, MD, PhD (Harvard/McLean) as Chief Medical Innovation Officer, bringing NIH- and DARPA-funded expertise in D-cycloserine and TMS for depression, PTSD, and suicidality.","length":201,"tagName":"p"}]},{"val":[{"type":"te...